Introduction
Cardiovascular diseases are increased remarkably in the past decade and are one of the most common causes of death in the patients with type 2 diabetes. A line of recent investigation examined the mechanisms of atherosclerosis from various view points and clarified that the proliferation of vascular smooth muscle cells (VSMCs) plays an important role in the development of atherosclerotic plaque (1) . However, the precise alterations in the intracellular signal transduction, which forces VSMCs to proliferate, remain to be elucidated. A number of large interventional studies have shown that HMG-CoA reductase inhibitors, statins, prevent the occurrence of cardiovascular diseases in Caucasians and Japanese (2) (3) (4) . In addition to a cholesterol-lowering effect, statins have pleiotropic effects on various vascular cells including endothelial cells, VSMCs, and mesangial cells (5) (6) (7) (8) . Although these direct effects may contribute to the preventive effect of statins on cardiovascular diseases, the precise extent of the contribution remains unclear.
The pleiotropic effects of statins are considered to be mediated by changes in the activation of small G proteins including Ras, Rho and Rac, which play a critical role in intracellular signal transduction. As an initial activation step, small G proteins undergo prenylations, including farnesylation and geranylgeranylation, which make these proteins hydrophobic and capable of translocating from cytosol to the plasma membrane. The synthesis of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are both intermediates of cholesterol synthesis, involves one of the rate-limiting pathways for the regulation of small G proteins. Several investigations including our study, have shown that statins suppress the translocation of small G proteins from the cytosol to the plasma membrane by inhibiting prenylation (8) (9) (10) (11) . However, the target small G proteins addressed by statins may depend on the kinds of stimulants are under investigation. In this study, we aimed to examine the contribution of Rho and its noble effector, Rho kinase, to the mechanism of platelet-derived growth factor (PDGF) -BB-induced proliferation of VSMCs, and clarify the role of the pleiotropic effects of statins in the treatment of atherosclerosis.
Materials and methods

Materials
The following reagents were obtained: PDGF-BB (PEPRO TECH EC Ltd, London, England), a PDGF-β receptor specific blocker, Ki6896 (Kirin Brewery, Gunma, Japan), cerivastatin (Cst) (Bayer AG, Wuppertal, Germany), a Rho kinase specific inhibitor, Y-27632 (Yoshitomi pharmaceutical industries, Saitama, Japan), geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) (Sigma, St. Louis, MO, USA), a selective inhibitor of farnesyltransferase, FTI-277, and a selective inhibitor of geranylgeranyltransferase-1, GGTI-286 (CALBIOCHEM, Bad Soden, Germany), [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]L-Ornithine hydrochloride (Moravek Biochemicals, Brea, CA, USA), a monoclonal antibody against Rho A (26C4) (Santa Cruz, Heidelberg, Germany), [methyl- The cell line of VSMCs established from embryo rat thoracic aorta, A7r5 (12), was purchased (American Type Culture Collection, Manassas, VA, USA). Dulbecco's modified Eagle medium (DMEM) and fetal bovine serum (FBS) were purchased (GIBCO, Grand Island, NY, USA).
Cell Culture
A7r5 was cultured in DMEM supplemented with 10% FBS, 100 units/ml penicillin G sodium, 100 µg/ml streptomycin sulfate and 0.25 µg/ml amphotericin B, kept at 37°C in a humidified atmosphere with 5% CO2.
Assay for extracellular signal-regulated kinase (ERK1/2)
The activity of extracellular signal-regulated kinase (ERK1/2) was measured by using an p44/42 MAP kinase assay kit as described previously (13) . The subconfluent VSMCs were starved in serum-free medium for 24 hours, and then 20 ng/ml PDGF-BB was added to the medium. The cells were preincubated with 0.5 µM Ki6896, 2 µM Cst, 5 µM FTI-277, 5 µM GGTI-286, 10 µM Y-27632, 10 µM FPP, or 10 µM GGPP respectively for 6 hours before the addition of PDGF-BB. After being stimulated by PDGF-BB for 10 minutes, the cells were rinsed with icecold phosphate-buffered saline (PBS) and scraped with lysis buffer (20 mM Tris, pH7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, 1 mM PMSF). The lysate was sonicated at 4°C for 30 seconds. The homogenate was centrifuged at 8,000rpm at 4°C for 10 minutes and the supernatant was used for the assay of ERK1/2. The protein content of the supernatants was determined by BCA method (14) . The samples were incubated with a monoclonal antibody for ERK1/2 over-night at 4°C and centrifuged. The immunoprecipitates were incubated with Elk-1 fusion protein as a substrate in the presence of ATP and kinase buffer (25mM Tris, pH7.5, 5mM β-glycerolphosphate, 2mM DTT, 0.1mM Na3VO4, 10mM MgCl2). The phosphorylation of Elk-1 at Ser383 was immunoblotted using an anti-phospho-Elk-1 antibody, and was visualized using the enhanced chemiluminescence (ECL) detection system (15) . The intensity was measured by densitometer.
DNA synthesis
DNA synthesis was assessed by measuring [ 3 H] thymidine incoporation in the cells. VSMCs were plated at 4 ×10 4 cells onto 3.5cm dishes. After 2 days of culture, the subconfluent cells were starved in serum-free medium for an additional 24 hours. After preincubation with 0.5 µM Ki6896, 2 µM Cst, 5 µM FTI-277, 5 µM GGTI-286, 10 µM Y-27632, 10 µM FPP, or 10 µM GGPP for 60 minutes, 20ng/ml PDGF-BB was added and the culture was continued for another 18 hours. The cells were pulse-labeled with [ 3 H] thymidine for the final 10 hours, followed by scraping and precipitating with 5% trichloroacetic acid. After washing, [ 3 H] radioactivity was solubilized in 1 M NaOH and determined by liquid scintillation counter.
Assay for ornitihine decarboxylase (ODC) activity
For the assay of ornitihine decarboxylase (ODC) activity, the cells were broken down by three cycles of thawing and freezing to yield cytosol fractions. ODC activity was determined in the cytosol fractions by measuring the production of radioactively labeled CO2 from [1-14 C] L-Ornithine hydrochloride (16) . One unit of ODC activity was defined as the amount releasing 1nM of CO2 from ornithine/h at 37°C.
Assay for Rho A protein in membrane fractions
The cells were preincubated with each experimental agent for 6 hours, followed by stimulation with 20 ng/ml PDGF-BB for another 24 hours. The cells were then scraped with lysis buffer (250 mM sucrose, 10 mM EGTA, 2 mM EDTA, 20 mM Tris-HCl, pH 7.5, 1 mM PMSF, 0.1% leupeptin and 0.1% aprotinin) and broken down by sonication. The samples were centrifuged at 100,000 × g at 4°C for 45 minutes to obtain membrane fractions in the precipitates. The membrane fractions were resuspended in lysis buffer. For Western blot analysis, 150 µg of membrane proteins was applied to 15% SDS-PAGE. Immunoblotting was accomplished using a monoclonal antibody for Rho A. Immunodetection was carried out by using a peroxidase-conjugated anti-mouse secondary antibody and detected with the ECL detection system.
Statistical analysis
Data were expressed as the mean ± S.D. To compare the mean values, Student's t-test was used with p < 0.05 indicating statistical significance.
Results
PDGF-BB-induced ERK1/2 activities in VSMCs
After stimulation with 20 ng/ml PDGF-BB, the ERK1/2 activity in VSMCs increased to a peak at 10min and thereafter declined (data not shown). Pretreatment of the cells with Ki6896 and Cst resulted in the inhibition of this PDGF-BB-induced activation of ERK1/2. GGTI-286 also suppressed the PDGF-BB-induced activation of ERK1/2, whereas FTI-277 had no effect. Y-27632 also suppressed activation of ERK1/2 (Fig. 1a) . The inhibitory effect of Cst on the PDGF-BB-induced the activation of ERK1/2 was completely reversed by the addition of GGPP. On the other hand, the addition of FPP had no effect (Fig. 1b) . These data indicate that the inhibitory effect of Cst on the PDGF-BB-induced activation of ERK1/2 is mediated through the suppression of proteins geranylgeranylation.
PDGF-BB-induced proliferation of VSMCs
The (Fig.  2a) . The inhibitory effect of Cst on the PDGF-BB-induced incorporation of [ 3 H] thymidine was completely reversed by the addition of GGPP. In contrast, the addition of FPP showed no influence on the effect of Cst (Fig. 2b) . These data indicate that the inhibitory effect of Cst on the PDGF-BB-induced proliferation of VSMCs is mediated through the suppression of proteins geranylgeranylation.
PDGF-BB-induced the activation of ODC in VSMCs
ODC is a rate-limiting enzyme in the synthesis of polyamines which plays an essential role in cell proliferation (17) . PDGF-BB had induced the activation of ODC in VSMCs, peaking after 10 hours (Fig. 3) . The ODC activation by PDGF-BB was completely inhibited by Ki6896 and Cst. GGTI-286 and Y-27632 also suppressed the PDGF-BB-induced ODC activation which was not affected by FTI-277 (Fig. 4a) . The inhibitory effect of Cst on the PDGF-BB-induced activation of ODC was completely reversed by the addition of GGPP, but not FPP. (Fig. 4b) .
PDGF-BB-induced traslocation of Rho A to the plasma membrane in VSMCs
Rho A protein in the membrane fractions of VSMCs was increased by stimulation with PDGF-BB as compared with the control cells. The PDGF-BB-induced increment in membrane-bound Rho A had been completely inhibited by Cst and GGTI-286. FTI-277 had no effect on the translocation of Rho A to the membrane (Fig. 5a ). The inhibitory effect of Cst on the PDGF-BB-induced increment in membrane-bound Rho A was completely reversed by the addition of GGPP. In contrast, FPP had no effect on the translocation Rho A to the membrane (Fig. 5b) . These data indicate that PDGF-BB induces Rho A translocation in VSMCs, which is inhibited by Cst through the suppression of Rho A geranylgeranylation. 
Discussion
PDGF is significant in the development of atherosclerosis, stimulating the proliferation and migration of VSMCs in an autocrine, and/or paracrine manner (18) . However, the exact intracellular mechanism by which VSMCs respond to PDGF remains to be investigated. PDGF-BB causes tyrosine phosphorylation and dimerization of the kinetic domains of the PDGF-β receptor which leads to the activation of the mitogen-activated protein (MAP) kinase cascade.
In this study, we aimed to identify small G protein, which contributes to the signal transduction mediating the PDGF-BB-induced proliferation of VSMCs. PDGF-BB stimulated the activation of ERK1/2 in cultured VSMCs, which had been completely inhibited by Cst and a PDGF-β receptor specific blocker, Ki6896 (Fig 2a) . As the geranyl geranyl transferase inhibitor, GGTI-286, also suppressed the PDGF-BB-induced activation of ERK1/2, that the inhibition of the PDGF-BB-induced activation of ERK1/2 by Cst was fully recovered with the addition of GGPP, but not FPP (Fig. 2b) , this indicates that the PDGF-BB-induced activation of ERK1/2 depends on the geranylgeranylation of small G proteins in VSMCs. PDGF-BB augmented [ 3 H] thymidine incorporation and ODC activities in the cultured VSMCs, which was completely inhibited by Cst and Ki6896 (Fig. 3a, 4a) . As GGTI-286 also suppressed the PDGF-BB-induced augmentation of [ 3 H] thymidine incorporation and the activation of ODC in VSMCs and the inhibitory effect of Cst was recovered by the addition of GGPP, but not FPP (Fig. 3b, 4b) , indicate the PDGF-BBinduced proliferation of VSMCs is thought to be mediated through the activation of ERK1/2, which may be regulated by geranylgeranylated small G proteins. We have found that the translocation of Rho A, a major geranylgeranylated small G protein, is upregulated by the stimulation of PDGF-BB in VSMCs stimulated with PDGF-BB (Fig. 5) . These data suggest that the PDGF-β receptor binding with PDGF-BB stimulates Rho GTPase activity, which leads to the proliferation of VSMCs via the activation of ERK1/2. It is also suggested that HMG-CoA reductase inhibitor, Cst, suppresses the geranylgeranylation of Rho A, resulting in the inhibition of the PDGF-BB-induced proliferation of VSMCs. This mechanism may contribute to the pleiotropic effects of statins by which they can prevent the progression of atheroscerosis independently of plasma lipid levels.
Several studies have investigated a positive contribution of small G protein(s) to PDGF-BB-induced cell proliferation using statins. Binding to PDGF-BB, the PDGF-β receptor is shown to form a complex with the Rho family which is sensitive to ADP-ribosyltransferase C3 exoenzyme (19) . Laufs et al. have found that the downregulation of p27 kip by Rho GTPase mediates the PDGF-BB-induced proliferation of VSMCs, which is suppressed by simvastatin (20) . Short-term treatment of VSMCs with pravastatin has also shown an inhibitory effect on PDGF-BB-induced proliferation via stabilizing the Rho A protein (21) . These studies and our present study agree on the important role of Rho in the proliferation of VSMCs induced by PDGF-β receptor ligand. However, the mechanism whereby PDGF-β receptor stimulates Rho GTPase and the effector molecules existing downstream of Rho remains to be resolved. Candidate molecules are phosphatidylinositol-3 kinase (PI3 kinase) (21), retinoblastoma gene product (Rb) (20) , and focal adhesion kinase (FAK) (22) . In this regard, an another important finding of this study is the contribution of Rho kinase to the PDGF-BB-induced proliferation of VSMCs as an effector of Rho. In this study, Y-27632, a specific inhibitor of Rho kinase, suppressed both PDGF-BB-induced activation of ERK1/2 and proliferation of VSMCs, the indicating involvement of Rho kinase in the PDGF-BB-induced proliferation of VSMCs. Rho kinase/ROK/ROCK, identified as a downstream effector of Rho A, phosphorylates the myosin-binding subunit of myosin phosphatase and enhances smooth muscle cell contraction (23) . Rho A binds and subsequently activates Rho kinase, a family of serine/threonine kinases (24) . Rho kinase is thought to be involved in multiple cellular processes, including cytoskeltal organization, gene expression and transformation in various cell species (25) (26) (27) . Recently, a line of evidence showed an important role of Rho kinase in the development of atherosclerosis. Rho kinase participates in the thrombin-stimulated proliferation of VSMCs (28) and oxidized LDL-induced contraction of endothelial cells (29) . It is also reported that angiotensin II-induced monocyte chemoattractant protein-1 (MCP-1) gene expression (30) and plasminogen activator inhibitor type-1 (PAI-1) gene expression (31) are mediated by Rho Kinase. Moreover, the in vivo gene transfer of dominantnegative Rho-kinase induces the regression of experimental coronary arteriosclerosis in pigs (32) . These studies suggest that Rho kinase may play significant role (s) in the various aspects of atheroscleosis progression. However, the precise contribution mechanism of Rho kinase remains to be determined. This study is the first to reveal the significant participation of Rho A and Rho kinase in the PDGF-BB-induced proliferation of VSMCs. In this study, a close relationship has been demonstrated between the upregulation of Rho A and activation of ERK1/2, MAP kinase family, suggesting that ERK1/2 may mediate Rho GTPase signaling. There is no other report which has investigated the direct involvement of ERK1/2 in the Rho-Rho kinase cascade.
This study offers new insight into the role of Rho kinase in terms of the PDGF-BB-induced proliferation of VSMCs, which is considered to be the central process of atherosclerosis. However, the precise contribution mechanism of Rho kinase showed to be further investigated. On the basis of these data, we conclude that PDGF-β receptor binding to PDGF-BB stimulates Rho GTPase activity, which leads to the proliferation of VSMCs via the activation of ERK1/2. In this process, Rho kinase has an important role as an effector protein of Rho A. Statins suppress Rho A geranylgeranylation resulting in the inhibition of the PDGF-BB-induced proliferation of VSMCs as a pleiotropic effect. Rho A and Rho kinase are new target molecules which should be targeted by anti-atherosclerotic pharmacological therapies in future.
